Reported 266,700 shares, up 239,000 (862.8%) from the prior quarter.
Reported value 1141.2%; share count 862.8% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2025-09-30 | 880309 |
| 2025-12-31 | 854615 |
| 2026-03-31 | 0 |
| 2026-06-30 | 1165062 |
| 2026-09-30 | 14460474 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Added | 266,700 | +239,000 (862.8%) | 14.92% | $14,460,474 | 2026-11-02 | |
| Q2 2026 | New | 27,700 | +27,700 (0.0%) | 1.9% | $1,165,062 | 2026-08-04 | |
| Q1 2026 | Reduced | 0 | -29,500 (-100.0%) | 0 | $0 | 2026-05-06 | |
| Q4 2025 | Reduced | 29,500 | -2,200 (-6.9%) | 1.19% | $854,615 | 2026-02-05 | |
| Q3 2025 | New | 31,700 | +31,700 (0.0%) | 0.69% | $880,309 | 2025-11-03 |
Who else reported the position
349 managers reported ARK GENOMIC REVOLUTION ETF (DE for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| JPMorgan Chase & Co | Reduced | 6,972,027 | -471,269 | 0.02% | $376,140,889 | 28 qtrs |
| MORGAN STANLEY | Added | 6,927,982 | +204,771 | 0.02% | $375,635,261 | 37 qtrs |
| Bank of America Corporation | Added | 2,521,149 | +1,606,472 | < 0.01% | $136,696,680 | 35 qtrs |
| The Goldman Sachs Group Inc | Reduced | 2,206,762 | -810,201 | 0.01% | $119,650,636 | 24 qtrs |
| JEFFERIES FINANCIAL GROUP INC | Reduced | 1,500,000 | -300,113 | 0.6% | $81,330,000 | 3 qtrs |
| UBS Group AG | Reduced | 1,266,746 | -319,099 | < 0.01% | $68,682,968 | 35 qtrs |
| STATE OF WISCONSIN INVESTMENT BOARD | Added | 1,109,799 | +75,423 | 0.12% | $60,173,302 | 20 qtrs |
| LPL Financial LLC | Added | 1,028,563 | +110,931 | 0.01% | $55,768,667 | 39 qtrs |
| CITADEL ADVISORS LLC | New | 779,104 | +779,104 | < 0.01% | $42,243,019 | 34 qtrs |
| Citigroup Inc | Reduced | 689,700 | -1,482,615 | 0.01% | $37,395,534 | 35 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- November 02, 2026
- Filing type
- 13F-HR
- Position type
- GENOMIC REV ETF
Voting authority reported
- Sole
- 266,700
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.